The global in-vitro fertilization (IVF) market size was valued at around USD 15 billion in 2017 and is expected to grow at a CAGR of around 10%. Increase in cases of infertility and development of advanced technologies such as lens less imaging of the sperms are likely to drive the market in coming years.
According to the American Society for Reproductive Medicine (ASRM), the inability to have a child affects around 6.7 million women in the U.S, which accounts for around 11.0% of the reproductive population. Moreover, 25% of the couples have more than one factors leading to infertility.
The average age of women and men getting married and having their first child is increasing. This trend has increased the number of women seeking the IVF treatment. Moreover, to focus on their career, many women freeze their eggs to have the child at a later.
The government funding to encourage egg/sperm freezing to bring down the chances of multiple pregnancies, technological advancements that enable pre-identification of the genetic disorder, and various industrial revolutions are expected to boom the market growth.
In December 2016, the Ontario government announced a USD 50 million fertility program to cover IVF treatment for 5,000 people. Furthermore, the Singapore government offers around 75% co-funding for various ART procedures such as In-Vitro Fertilization (IVF), gamete intrafallopian transfer (GIFT) and intracytoplasmic sperm injection (ICSI).
In January 2015, the Centers for Disease Control and Prevention (CDC) reported that the use of ICSI has increased from 36.4% in 1996 to around 76.2% in 2012. The percentage has almost doubled over the years hence the segment dominated in the overall IVF market.
To increase the success rate of the IVF, researchers have introduced techniques that are used prior to the IVF procedure. Presently, advanced techniques, such as assisted hatching, vitrification, egg/sperm freezing, Percutaneous Epidydimal Sperm Aspiration and Testicular Sperm Extraction (PESA and TESE), mini IVF, three-parent IVF and genetic diagnosis, are used.
With the use of PGD technique, scientists can easily identify the diseased DNA and can change it with the healthy donor DNA, thereby ensuring a healthy childbirth. With the expected demand, industry players are bringing in new molecular diagnostic techniques, which could further enhance the IVF treatment rate.
In April 2016, CombiMatrix Corporation launched Combi PGD, a diagnostic technique used prior to embryo implantation. Introduction of technologically advanced systems by the market players such as Embryoscope Time-Lapse System (Vitrolife AB) is one of the high impact rendering drivers.
The market has been segmented into fresh embryo (own eggs), frozen embryo (own eggs), fresh embryo (donor eggs), frozen embryo (donor eggs). Fresh Embryo (Own Eggs) segment accounted for the largest share of the market due to the high success rate in the first attempt.
Frozen embryo (own eggs) segment is likely to witness the fastest growth in coming as the procedure is performed in complicated cases such as on a patient suffering from ovarian hyperstimulation syndrome (OHSS). Additionally, better implantation rates, higher live birth rates, more birth weight, lower miscarriage rates, and lower ectopic pregnancy are expected to increase the demand for procedure.
The IVF instrument consists of culture media, capital equipment, and IVF disposable devices. In 2014, culture media accounted for the largest share of the market. This can be attributed to high government funding, increase in research activities to improve the culture media, and ability to preserve sperm without reducing their quality.
Cryopreservation media, semen processing media, ovum processing media, and embryo culture media are the major media used during IVF procedure. With the establishment of huge egg cryobanks, the demand for egg processing media is also expected to increase in the coming years.
With the increasing number of patient opting for IVF and gamete freezing, the demand or capital equipment is anticipated to witness growth. Industries are developing equipment with high automation standards.
Fertility clinics are providing state-of-the-art equipment such as micromanipulation, non-invasive Radio Frequency Identification (RFID) tags, and others, which are further expected to propel the market growth over the forecast period. With the need for high standards of sterile conditions and strict regulatory mandates, industry players are in a process of introducing disposable devices such as needles, slides, chambers, and others.
Fertility clinics held the largest market share in 2017 and is likely to dominate throughout the forecast period. With rise in demand for ART treatments, the number of fertility clinics and ART centers is increasing considerably. Licensed fertility clinics offer counselling to couples having problems in conceiving. Based on the severity of their problems, doctors and specialists plan out IVF treatments for couples.
In 2014, Europe dominated the in-vitro fertilization market, as it is the first one to come up with the in-vitro fertilization procedure, to remove the title experimental from cryopreservation of eggs, and the first one to legally approve the three parents IVF or the mitochondrial transfer technique.
Furthermore, medical tourism in Europe is driving the growth of the IVF market. People are flying to the Czech Republic from the U.S. due to the cheaper IVF carried out as compared to the U.S. Institutes are introducing newer techniques, which can offer better success rate at an affordable cost. For instance, the Valencian Infertility Institute in Spain has developed various fertility methods to increase the treatment success rates.
Germany, France, and the UK are the major contributing countries in the region. In France every year, about 19,000 ART births take place. Furthermore, in July 2015, France legislation allowed legal recognition to surrogate children in order to enable them to have French nationality and enjoy the same rights as other French children.
North America is also expected to witness increasing demand for the fertility treatment in the coming years. In April 2016, Reprogenetics published its research, which validated the use of High-Resolution Next Generation Sequencing (HR-NGS) techniques. The company which is the largest genetic laboratory in the U.S. provides Pre-Implantation Genetic Diagnosis for Aneuploidy (PGD-A). The new test detects the mosaic embryos, which can help in selecting healthy embryo during IVF. Moreover, the Toronto Centre for Advanced Reproductive Technology (TCART) was the first Canadian Clinic to provide free IVF to 60 women to experiment the AUGMENT rejuvenating technique. The technique allowed older cells to rejuvenate by taking smaller cells from the outer ovary lining. This process allowed young cell harvesting and higher treatment success rate.
The demand for IVF treatment is expected to boom in the Asia Pacific region due to fertility tourism, increasing foreign investment to penetrate in the economically developing countries, and the changing regulatory landscape. In November 2017, Warburg Pincus, a private equity firm, was in the last stage of negotiations to procure minority stake in Indira IVF Hospital Pvt. Ltd, which is one of the leading fertility hospital chains in India.
IVF market has a huge opportunity in Japan owing to the introduction of newer techniques such as AUGMENT and defined regulatory framework. IN August 2016, OvaScience announced the finalization of its commercial agreement with IVF Japan Group, through which AUGMENT treatment would be made available to women.
In Japan, the couples can apply for co-funding for a maximum of three cycles with USD 1,920 for each cycle. The couple, whose income is over USD 94,000 per year cannot qualify for the funding option.
In January 2013, Oocyte Donation Network (OD-NET), first Japanese NPO bank was started and in May 2013, thirty-eight women were eligible, out of the 100 who applied. This organization only funds for the actual expenses and not for the eggs. Surrogacy has been banned by the Japan Society of Obstetrics and Gynecology and Health, Labor, and Welfare Ministry.
The Asia Pacific Initiative on Reproduction (ASPIRE), the task force of clinicians and scientists are involved in the monitoring and management of fertility and Assisted Reproductive Technology (ART). It promotes awareness of the ART and infertility and enhances the infertility-related services in the region.
Researchers from the University of Adelaide in Australia and the University of Medicine and Pharmacy in Vietnam in the study (The New England Journal of Medicine) showed that the pregnancy and live birth rates were equal in the group of women implanted with fresh embryos compared with frozen embryos.
In January 2018, it was announced that Singapore Medical Group (SMG) took the stake in City Fertility Centre or CFC Global, which is one of the leading IVF specialists in Australia. The partnership is expected to increase referrals in Vietnam and other nations due to increasing demand for fertility and women’s health.
Technological advancements is expected to drive the Australian IVF market over the forecast period. In March 2018, it was reported that smart TV app is used by the Monash IVF to consult fertility patients in China, after the clinic entered into an agreement with AC International Medical Tourism (Melbourne), which targets Chinese market. Monash IVF, fertility clinic in Melbourne, entered into a partnership with platform BabySmart, which enables the Chinese patients to have face to face consultation with the clinicians in Australia.
Key industry contributors are OvaScience, EMD Serono Inc., Vitrolife AB, Irvine Scientific, Cook Medical Inc., Cooper Surgical Inc., Genea Biomedx, Thermo Fisher Scientific Inc., Progyny, Inc., and Boston IVF.
Development of innovative product & their commercialization, mergers and geographical expansion are the key strategies of the market players. In August 2015, OvaScience announced the results of its first published analysis comparing AUGMENT fertility treatment with a standard IVF. The results showed a significant higher rate of selection and transfer of embryos as compared to the standard treatment. In May 2015, EMD collaborated with Genea Biomedx to strengthen its position in the fertility market by providing fertility technologies.
Base year for estimation
Actual estimates/Historic data
2014 - 2017
2018 - 2025
Revenue in USD Million & CAGR from 2018 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, UK, Germany, France, Japan, China, India, Brazil, Mexico, South Africa
Revenue forecast, company share, competitive landscape, growth factors & trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth and provides an analysis of the industry trends in each of the sub segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the In-vitro Fertilization (IVF) market based on instruments, type, end use, and region:
Instrument Outlook (Revenue, USD Million; 2014 - 2025)
Type Outlook (Revenue, USD Million; 2014 - 2025)
End-use Outlook (Revenue, USD Million; 2014 - 2025)
Regional Outlook (Revenue, USD Million; 2014 - 2025)
Middle East & Africa
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."